PF-562271

Name: PF-562271
Brand: Selleck Chemicals
SKU: S2890
Rating: 5 (83 reviews)

For research use only.

Catalog No.S2890

83 publications

CAS No. 717907-75-0

PF-562271 is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM in cell-free assays, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs.

Selleck's PF-562271 has been cited by 83 publications

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

J Clin Invest, 2020, 1;130(5):2422-2434

PubMed: 32250340 ( click the link to review the publication )

Nat Commun, 2020, 11(1):3282

PubMed: 32612176 ( click the link to review the publication )

EMBO Mol Med, 2020, e12010

PubMed: 33025708 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2020, 15

PubMed: 32485098 ( click the link to review the publication )

Cell Rep, 2020, 30(6):1780-1797

PubMed: 32049010 ( click the link to review the publication )

Elife, 2020, 4;9:e50571

PubMed: 32017701 ( click the link to review the publication )

Cell Death Dis, 2020, 14;11(4):230

PubMed: 32286266 ( click the link to review the publication )

Aging (Albany NY), 2020, 7;12(9):8221-8240

PubMed: 32379705 ( click the link to review the publication )

Sci Rep, 2020, 10(1):419

PubMed: 31942012 ( click the link to review the publication )

J Biol Chem, 2020, jbc.RA120.012957

PubMed: 32934005 ( click the link to review the publication )

J Biol Chem, 2020, 12 pii: jbc

PubMed: 32280065 ( click the link to review the publication )

Cell Cycle, 2020, 14:1-13

PubMed: 32286145 ( click the link to review the publication )

Cells, 2020, 9(1)

PubMed: 31905606 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(2):637-649

PubMed: 31784455 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(14):4552-4566

PubMed: 30979745 ( click the link to review the publication )

Sci Signal, 2019, 12(565)

PubMed: 30670633 ( click the link to review the publication )

Cell Death Dis, 2019, 10(10):738

PubMed: 31570694 ( click the link to review the publication )

J Biol Chem, 2019, 294(18):7221-7230

PubMed: 30846565 ( click the link to review the publication )

J Tissue Eng Regen Med, 2019, 13(4):625-636

PubMed: 30770650 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2019, 145(6):1461-1469

PubMed: 31006845 ( click the link to review the publication )

Molecules, 2019, 24(10)

PubMed: 31109130 ( click the link to review the publication )

J Pharm Biomed Anal, 2019, 168:163-173

PubMed: 30807921 ( click the link to review the publication )
Mol Med Rep, 2019, 19(6):4753-4760

PubMed: 31059085 ( click the link to review the publication )

Zygote, 2019, 27(3):173-179

PubMed: 31171046 ( click the link to review the publication )

Cell Rep, 2018, 22(10):2784-2796

PubMed: 29514104 ( click the link to review the publication )

Oncogene, 2018, 37(22):2953-2966

PubMed: 29515233 ( click the link to review the publication )

Oncogene, 2018, 37(23):3166-3182

PubMed: 29545604 ( click the link to review the publication )

Cell Death Dis, 2018, 9(9):848

PubMed: 30154481 ( click the link to review the publication )

Cancer Sci, 2018, 109(12):3783-3793

PubMed: 30281878 ( click the link to review the publication )

J Am Heart Assoc, 2018, 7(18):e008604

PubMed: 30371220 ( click the link to review the publication )

J Cell Sci, 2018, 131(10)

PubMed: 29678906 ( click the link to review the publication )

Stem Cells Int, 2018, 2018:2190657

PubMed: 30275837 ( click the link to review the publication )

Int J Oncol, 2018, 53(4):1544-1556

PubMed: 30066854 ( click the link to review the publication )

Acta Pharmacol Sin, 2018, 10.1038/aps

PubMed: 29417941 ( click the link to review the publication )

Cell Cycle, 2018, 17(23):2577-2592

PubMed: 30488756 ( click the link to review the publication )

Oncol Rep, 2018, 40(4):2325-2333

PubMed: 30106432 ( click the link to review the publication )

Cancer Epidemiol Biomarkers Prev, 2018, 27(7):805-813

PubMed: 29654156 ( click the link to review the publication )

Sci Transl Med, 2017, 9(420)

PubMed: 29237758 ( click the link to review the publication )

Nat Commun, 2017, 8:14122

PubMed: 28098159 ( click the link to review the publication )

Mol Syst Biol, 2017, 13(1):905

PubMed: 28069687 ( click the link to review the publication )

Cancer Sci, 2017, 108(7):1347-1356

PubMed: 28406574 ( click the link to review the publication )

FEBS J, 2017, 284(17):2856-2869

PubMed: 28665039 ( click the link to review the publication )

Sci Rep, 2017, 7(1):4032

PubMed: 28642549 ( click the link to review the publication )

Mol Carcinog, 2017, 56(12):2558-2565

PubMed: 28667800 ( click the link to review the publication )

Cancer Manag Res, 2017, 9:879-889

PubMed: 29276408 ( click the link to review the publication )

Cell Signal, 2017, 38:1-9

PubMed: 28647573 ( click the link to review the publication )
Oncol Rep, 2017, 38(1):63-70

PubMed: 28560386 ( click the link to review the publication )

Onco Targets Ther, 2017, 10:5817-5826

PubMed: 29263678 ( click the link to review the publication )

Evid Based Complement Alternat Med, 2017, 2017:4535326

PubMed: 29234400 ( click the link to review the publication )

Mol Med Rep, 2017, 16(6):8937-8943

PubMed: 28990104 ( click the link to review the publication )

Oncotarget, 2017, 8(43):75102-75113

PubMed: 29088849 ( click the link to review the publication )

Biophys J, 2017, 113(7):1585-1598

PubMed: 28844472 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47931-47942

PubMed: 28624785 ( click the link to review the publication )

Nat Cell Biol, 2016, 18(2):168-80

PubMed: 26689676 ( click the link to review the publication )

Nat Commun, 2016, 7:10354

PubMed: 26838601 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(23):5851-5863

PubMed: 27220963 ( click the link to review the publication )

Cancer Res, 2016,

PubMed: 27216177 ( click the link to review the publication )

Cancer Lett, 2016, 376(1):188-96

PubMed: 26996299 ( click the link to review the publication )

Breast Cancer Res, 2016, 18(1):81

PubMed: 27495308 ( click the link to review the publication )

Oral Oncology, 2016, 10.1016/j.oraloncology.2016.05.010

PubMed: ( click the link to review the publication )

Sci Rep, 2016, 6:36214

PubMed: 27796369 ( click the link to review the publication )

J Biol Chem, 2016, 291(15):8140-9

PubMed: 26865633 ( click the link to review the publication )

Mol Pharmacol, 2016, 89(5):521-40

PubMed: 26895766 ( click the link to review the publication )

J Proteome Res, 2016, 15(12):4369-4386

PubMed: 27762562 ( click the link to review the publication )

Int J Biochem Cell Biol, 2016, 71:62-71

PubMed: 26693891 ( click the link to review the publication )

Oncotarget, 2016, 7(30):48093-48106

PubMed: 27344177 ( click the link to review the publication )

Sci Rep, 2016, 6:19261

PubMed: 26763933 ( click the link to review the publication )

Oncotarget, 2016, 7(29):45186-45198

PubMed: 27286256 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(11):1412-21

PubMed: 26436690 ( click the link to review the publication )

Elife, 2015, 4

PubMed: 26274564 ( click the link to review the publication )
Oncogene, 2015, 34(40):5114-27

PubMed: 25639872 ( click the link to review the publication )

Cell Physiol Biochem, 2015, 37(2):515-26

PubMed: 26330161 ( click the link to review the publication )

J Biol Chem, 2015, 290(14):8677-92

PubMed: 25713079 ( click the link to review the publication )

Environ Toxicol Pharmacol, 2015, 39(1):114-24

PubMed: 25481308 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2015, 112(20):E2595-601

PubMed: 25941386 ( click the link to review the publication )

Oncotarget, 2015, 6(27):23776-92

PubMed: 26068982 ( click the link to review the publication )

Oncotarget, 2015, 6(28):25755-69

PubMed: 26342198 ( click the link to review the publication )

Oncotarget, 2015, 6(3):1531-43

PubMed: 25605238 ( click the link to review the publication )

PLoS One, 2014, 9(2):e88587

PubMed: 24523919 ( click the link to review the publication )

Cancer Sci, 2013, 104(12):1618-25

PubMed: 24112719 ( click the link to review the publication )

Int J Clin Exp Pathol, 2013, 6(10):2082-91

PubMed: 24133586 ( click the link to review the publication )

Purity & Quality Control

Choose Selective FAK Inhibitors

Biological Activity

Description

Targets

FAK ^[1] (Cell-free assay)	PYK2 ^[1] (Cell-free assay)	CDK2/CyclinE ^[1] (Cell-free assay)	CDK3/CyclinE ^[1] (Cell-free assay)	CDK1/CyclinB ^[1] (Cell-free assay)	View More
1.5 nM	13 nM	30 nM	47 nM	58 nM	View More

In vitro

PF-562271 binds in the ATP-binding cleft of FAK, forming two of the three “canonical” H-bonds between the inhibitor and main-chain atoms in the kinase hinge region. PF-562271 is potent in an inducible cell-based assay measuring phospho-FAK with IC50 of 5 nM. PF-562271 (3.3 μM) results in G1 arrest of PC3-M cells. ^[1] PF-562271 (1 nM) blocks bFGF-stimulated blood vessel angiogenesis as performed in chicken chorioallantoic membrane assays. PF-262271 potently blocks blood vessel sprouting without detectable changes in vascular leakage. ^[2] PF-562271 (250 nM) results in complete inhibition of collective A431 cell invasion into collagen gels. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
MV-4-11	NWqwSnJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTFeVdkUUN3ME2wMlI4PjZizszN	M4LHcXNCVkeHUh?=
SW982	MmP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTnbWUxUUN3ME2wMlMzQDJizszN	M2TNT3NCVkeHUh?=
KM12	NF\pZYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2DIe2lEPTB;MD6zPFU2PyEQvF2=	MmfSV2FPT0WU
COLO-205	MmHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEjwV\|ZKSzVyPUCuOFg3PThizszN	NHLJ[3lUSU6JRWK=
COLO-829	NGmxeFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NULZPZd[UUN3ME2wMlc2OTd4IN88US=>	NWK0[IFDW0GQR1XS
MG-63	MnzxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEjrSVFKSzVyPUCuPFA3OzdizszN	M4q3fXNCVkeHUh?=
IGROV-1	MkW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWfPVnJ4UUN3ME2wMlgyODN6IN88US=>	NIfQcHlUSU6JRWK=
NCI-H650	M3\GcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mlr2TWM2OD1yLkizNVU1KM7:TR?=	M2S1UHNCVkeHUh?=
RT-112	MlLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;yZmVHUUN3ME2wMlk5PDZizszN	MV3TRW5ITVJ?
BCPAP	NEexS3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojFTWM2OD1zLkCxNlg5KM7:TR?=	MXLTRW5ITVJ?
ALL-PO	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXRTmdKSzVyPUGuNFE2QDRizszN	MYTTRW5ITVJ?
KYSE-270	NEDJO4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTFwMES3NVQh\|ryP	MkDQV2FPT0WU
8305C	Mo\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVPjcmdOUUN3ME2xMlA6QTB2IN88US=>	MYXTRW5ITVJ?
NCI-H810	NULG[Y93T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPNTZBvUUN3ME2xMlExPzd4IN88US=>	M2O2cXNCVkeHUh?=
CAL-33	MkHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nlb2lEPTB;MT6xNlk{QCEQvF2=	NU\LT\|VNW0GQR1XS
AN3-CA	M2DQNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrMNlc1UUN3ME2xMlIyQDZ5IN88US=>	M3PMO3NCVkeHUh?=
NKM-1	NYXpdFVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTFwMke1NFYh\|ryP	NEP3fGhUSU6JRWK=
BPH-1	NVjMR3N1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4izdmlEPTB;MT6yPFc3PiEQvF2=	MlP6V2FPT0WU
MES-SA	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTFwM{C2PFIh\|ryP	NF\PSHVUSU6JRWK=
CAL-62	MoPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\RXJVKSzVyPUGuN\|E6ODlizszN	NFfxUnJUSU6JRWK=
Detroit562	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XBRWlEPTB;MT6zOVIzOiEQvF2=	MlvBV2FPT0WU
KYSE-150	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rXeGlEPTB;MT6zOVI{PiEQvF2=	NVXxSWptW0GQR1XS
SK-UT-1	NFm0VZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{LFSWlEPTB;MT60OFY1PyEQvF2=	M1vHNHNCVkeHUh?=
HUTU-80	NVnFTWF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXBOXczUUN3ME2xMlQ1QDh4IN88US=>	M2C2OnNCVkeHUh?=
SIG-M5	NXvzSHR4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jYWWlEPTB;MT60PFM5PyEQvF2=	MnXYV2FPT0WU
AGS	Moe1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HHWGlEPTB;MT61NlEzPCEQvF2=	NVfDeHVyW0GQR1XS
ST486	M{TGZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTFwNUOyO\|gh\|ryP	MnzOV2FPT0WU
HSC-2	NFP6WWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVX1RoxFUUN3ME2xMlU{QTVizszN	MVvTRW5ITVJ?
LCLC-103H	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LJ[GlEPTB;MT61OVgyQCEQvF2=	MlTXV2FPT0WU
BC-1	M1\qRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvzd\|lKSzVyPUGuOlE3PjRizszN	MVfTRW5ITVJ?
CGTH-W-1	NWnDVVVVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTFwNkG2O\|kh\|ryP	MXzTRW5ITVJ?
MZ1-PC	NUOyUFhnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MorHTWM2OD1zLk[yN\|EzKM7:TR?=	MkHGV2FPT0WU
SW1710	MmL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk[xTWM2OD1zLk[yOlI5KM7:TR?=	MnTQV2FPT0WU
EW-13	MkPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmLITWM2OD1zLk[zOFY3KM7:TR?=	NVjzenh{W0GQR1XS
TE-11	NF7NSXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUfBN3c4UUN3ME2xMlY{PTJ{IN88US=>	M4jaN3NCVkeHUh?=
BHY	M2\KWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoTrTWM2OD1zLk[1OlY{KM7:TR?=	MV;TRW5ITVJ?
ML-2	Mm\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnfwTWM2OD1zLk[2PFAzKM7:TR?=	NFHmSGpUSU6JRWK=
MEL-JUSO	NYf5eIxnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTFwN{K4PVEh\|ryP	MlrUV2FPT0WU
U251	M3fobGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFjzOHZKSzVyPUGuO\|QxOzFizszN	NVXyZ5V7W0GQR1XS
MHH-ES-1	NEjweZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NISwfHZKSzVyPUGuO\|k2PjhizszN	M{ftdHNCVkeHUh?=
CAL-85-1	NVrDbJZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH31eWxKSzVyPUGuPFA1QSEQvF2=	NUDwXZE2W0GQR1XS
D-336MG	NIPUXFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4nTWmlEPTB;MT64OVYyPCEQvF2=	MWHTRW5ITVJ?
VA-ES-BJ	NX\6VXRlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUS5bHFZUUN3ME2xMlkxOzF3IN88US=>	NGjmS3hUSU6JRWK=
MDA-MB-468	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnmyTWM2OD1zLkmxNlczKM7:TR?=	MVXTRW5ITVJ?
MEL-HO	Mo\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTFwOUe5PVMh\|ryP	NF\PXJdUSU6JRWK=
SW954	M2XTVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NILXfZhKSzVyPUKuNFAyPTFizszN	NIjUW3FUSU6JRWK=
LB831-BLC	MmCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn36TWM2OD1{LkCwPVg5KM7:TR?=	NW\rfop[W0GQR1XS
EW-16	NX3yUYN4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PJZWlEPTB;Mj6wN\|k5OyEQvF2=	Ml7jV2FPT0WU
NCI-H460	NH7aVW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3\0NWlEPTB;Mj6wOFg{QSEQvF2=	MYHTRW5ITVJ?
CHP-212	MmXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3Qe3hrUUN3ME2yMlA6PTN7IN88US=>	NH7JXFBUSU6JRWK=
MHH-NB-11	NFfaZmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1zOR2lEPTB;Mj6xNlgyQCEQvF2=	MnSxV2FPT0WU
DU-4475	M{PPfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLHcIdNUUN3ME2yMlE1PzV7IN88US=>	NHntRmhUSU6JRWK=
ABC-1	M{n5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTJwMkWxPVYh\|ryP	MlXqV2FPT0WU
LOUCY	MkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTJwMk[xNlgh\|ryP	M{WyNHNCVkeHUh?=
LC-2-ad	NEj3XXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;Dfm9KSzVyPUKuNlY6PjZizszN	NV3MUWVDW0GQR1XS
ETK-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\W[2lEPTB;Mj6yPFQ3KM7:TR?=	MlP0V2FPT0WU
KYSE-180	NH7Y[lBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoXuTWM2OD1{LkK4PFc1KM7:TR?=	MX;TRW5ITVJ?
HOP-92	M37ydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUDJR\|UxRTJwM{C2O\|Mh\|ryP	NHm4cG1USU6JRWK=
RCC10RGB	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXjZV4J1UUN3ME2yMlMzPTB5IN88US=>	M2\sV3NCVkeHUh?=
KASUMI-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2TqNmlEPTB;Mj6zNlg5KM7:TR?=	NHn5fm9USU6JRWK=
ACN	NInMV\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4rkVWlEPTB;Mj6zOFc1PSEQvF2=	NVTR[GNEW0GQR1XS
BxPC-3	NHSzTnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXKcFFKSzVyPUKuN\|U1OzZizszN	M1vtSXNCVkeHUh?=
MONO-MAC-6	NXz3[IF2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTJwNEGyOFgh\|ryP	MlP1V2FPT0WU
CAL-39	NGjnU5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWTJR\|UxRTJwNEG2Nlgh\|ryP	NGW5cHZUSU6JRWK=
CMK	NF\lVHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXrJR\|UxRTJwNEG3PVUh\|ryP	NHfqemhUSU6JRWK=
MFE-296	Mn7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2i4cmlEPTB;Mj60O\|c6OiEQvF2=	MUjTRW5ITVJ?
DU-145	MlXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTJwNEmxNVgh\|ryP	NYOz[oUzW0GQR1XS
MDA-MB-231	M1[1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnyflVKSzVyPUKuOFk2PzJizszN	NVPRZmRYW0GQR1XS
EFO-27	M2TtdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXrJR\|UxRTJwNUG4PFgh\|ryP	MWHTRW5ITVJ?
SNU-387	Mo\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHGXnVKSzVyPUKuOVI5OiEQvF2=	M1TUc3NCVkeHUh?=
KYSE-410	NFTuNINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PPUGlEPTB;Mj61OlUyPyEQvF2=	MWDTRW5ITVJ?
NCCIT	M2fUOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTJwNUeyOEDPxE1?	NEXPTZJUSU6JRWK=
LXF-289	M3vXWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1XZNWlEPTB;Mj61PFI4OyEQvF2=	NYO3UVdHW0GQR1XS
HMV-II	MlPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXq3c3BuUUN3ME2yMlU5QTl5IN88US=>	M3LWbnNCVkeHUh?=
MOLT-4	NXfUfVNKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2KxVmlEPTB;Mj62NFcyOiEQvF2=	NF[zdHZUSU6JRWK=
KOSC-2	MmmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWL0RplvUUN3ME2yMlY{QDd7IN88US=>	M4fnenNCVkeHUh?=
TUR	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUHJR\|UxRTJwNkWzOlkh\|ryP	NXH0[IR2W0GQR1XS
NCI-H2087	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTJwN{G2OFYh\|ryP	MkXlV2FPT0WU
SCC-15	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPUTWM2OD1{Lke1NlUzKM7:TR?=	M4X4VHNCVkeHUh?=
HSC-4	NIPaPGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnO3TWM2OD1{Lke4N\|g6KM7:TR?=	Mm[3V2FPT0WU
G-402	M2j4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTJwOEG0OFch\|ryP	NYWyZ49JW0GQR1XS
GP5d	MkLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2f1[mlEPTB;Mj64N\|gzPyEQvF2=	M{HQZXNCVkeHUh?=
IGR-1	NGLpd3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnLc3VKSzVyPUKuPFM6QDdizszN	NX;TU\|VjW0GQR1XS
SK-PN-DW	NVPQOYRiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTKNGVHUUN3ME2yMlg3OjB2IN88US=>	Ml\VV2FPT0WU
OPM-2	M3\NR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlnZTWM2OD1{Lki5PVc5KM7:TR?=	MV7TRW5ITVJ?
5637	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PlW2lEPTB;Mj65NlQ{QSEQvF2=	NHHDVWZUSU6JRWK=
NCI-H2030	NGPmcFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXHJR\|UxRTJwOUiwNlkh\|ryP	NVjpU5NDW0GQR1XS
SK-LU-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnQfmZCUUN3ME2yMlk5OzN2IN88US=>	NXHOOVRLW0GQR1XS
EW-18	NIDSNWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkT2TWM2OD1\|LkC1N\|Ih\|ryP	MkTxV2FPT0WU
786-0	NYXlNGZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rWN2lEPTB;Mz6wOVc5PCEQvF2=	NFP4[mhUSU6JRWK=
NCI-H1963	MnPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HDSmlEPTB;Mz6wPFgzPSEQvF2=	MnHQV2FPT0WU
A2780	NYf1OIs3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2HE[WlEPTB;Mz6xNFM1OSEQvF2=	NELJbmVUSU6JRWK=
NCI-H526	MoD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mme3TWM2OD1\|LkGzPVYyKM7:TR?=	NHXCbm9USU6JRWK=
BHT-101	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTNwMUW3PVgh\|ryP	MnXMV2FPT0WU
RPMI-7951	MlqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGniVXVKSzVyPUOuNlAyOzdizszN	NVTifFBuW0GQR1XS
HL-60	MlfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTNwMkGxOEDPxE1?	MoXSV2FPT0WU
CTV-1	NGHM[GxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTNwMkWzO\|ch\|ryP	NI\TU3dUSU6JRWK=
IST-SL1	M2rQdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXjFRo5DUUN3ME2zMlI6PDZ3IN88US=>	M3HKe3NCVkeHUh?=
G-401	NFu5eJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{XkW2lEPTB;Mz6yPVgxQCEQvF2=	M3T3VnNCVkeHUh?=
OVCAR-5	NYSxUpFLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTNwM{[zOVIh\|ryP	NHnNS45USU6JRWK=
EW-1	M1zQdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUfjXGtYUUN3ME2zMlQxPTR2IN88US=>	NYXIU4VYW0GQR1XS
H4	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXrOT21SUUN3ME2zMlQ4PTZ7IN88US=>	MYLTRW5ITVJ?
EM-2	NYnmSYRbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUj0Tm5{UUN3ME2zMlQ5Pjd2IN88US=>	NE\SXWdUSU6JRWK=
RS4-11	M4TXfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGruXZZKSzVyPUOuOFg4OTVizszN	MUjTRW5ITVJ?
NOMO-1	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrKb2xKSzVyPUOuOFkzODRizszN	NVnWTJNOW0GQR1XS
HCT-116	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1jEZ2lEPTB;Mz61NFcyOSEQvF2=	MXLTRW5ITVJ?
CAL-120	Mn7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLWTWM2OD1\|LkW3N\|Uh\|ryP	MX3TRW5ITVJ?
CAL-51	Mn3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkDTTWM2OD1\|LkW3OlEzKM7:TR?=	NXTvcHhlW0GQR1XS
RVH-421	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTNwNkCzNVEh\|ryP	M2jNNXNCVkeHUh?=
NCI-H2081	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFXMb49KSzVyPUOuOlUzQDhizszN	NYX0boRGW0GQR1XS
SBC-5	Ml;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTNwNke4PFIh\|ryP	NXX1[3VHW0GQR1XS
RL95-2	M2jrRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmHVTWM2OD1\|LkexPFY1KM7:TR?=	MoLFV2FPT0WU
SW872	MknqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTNwN{[5OVgh\|ryP	NVvPcmp{W0GQR1XS
VM-CUB-1	MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnj6TWM2OD1\|Lke3OVEh\|ryP	M{XCR3NCVkeHUh?=
SUP-T1	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PuW2lEPTB;Mz63PFMzKM7:TR?=	NEniXXBUSU6JRWK=
697	NFzPSFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mme4TWM2OD1\|LkixOlU4KM7:TR?=	MnPPV2FPT0WU
DBTRG-05MG	NFG3fo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rNPWlEPTB;Mz64NVY4PiEQvF2=	M4TENHNCVkeHUh?=
TE-441-T	NVS2N3dvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTNwOEK5N{DPxE1?	MWTTRW5ITVJ?
A204	MlntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4nw[2lEPTB;Mz65NFk2PiEQvF2=	NFLORXZUSU6JRWK=
HCC2998	NIW2SoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEK4Z3FKSzVyPUOuPVQ5PDNizszN	M3XVc3NCVkeHUh?=
SCC-4	M1y4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF:0fJZKSzVyPUOuPVU4QDJizszN	MoS5V2FPT0WU
ACHN	M{DiVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUi1OVlTUUN3ME20MlAzOzdizszN	MXrTRW5ITVJ?
NB1	NXHF[Yx4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTRwME[2OFQh\|ryP	NWfzRlhNW0GQR1XS
PANC-08-13	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTRwMEe3N{DPxE1?	M3HQ[nNCVkeHUh?=
A4-Fuk	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkDYTWM2OD12LkC3PFYyKM7:TR?=	MXnTRW5ITVJ?
NCI-H747	MoLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTRwMEi2O\|Qh\|ryP	NHLOWIZUSU6JRWK=
G-361	MlTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXfRNJlbUUN3ME20MlA6ODZizszN	M2jIfHNCVkeHUh?=
NCI-H292	M3XPVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFTTT3NKSzVyPUSuNFk1OjlizszN	MXvTRW5ITVJ?
HGC-27	NGi0bZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWTnfYZ5UUN3ME20MlA6PTR7IN88US=>	MV7TRW5ITVJ?
ATN-1	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\IdlRKSzVyPUSuNVA4PzdizszN	M{jJS3NCVkeHUh?=
RPMI-2650	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV7UTYNlUUN3ME20MlEzQTd3IN88US=>	M37EcHNCVkeHUh?=
SIMA	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NILLOolKSzVyPUSuNVQ1KM7:TR?=	M2fEOnNCVkeHUh?=
CA46	NYDmfVZsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTRwMU[xNFQh\|ryP	MX\TRW5ITVJ?
CHL-1	MmizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXHx[ZlFUUN3ME20MlE5QTZzIN88US=>	NETPeGxUSU6JRWK=
TE-10	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFrlV5VKSzVyPUSuNlI5QDdizszN	MmOzV2FPT0WU
NCI-H1734	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TJcmlEPTB;ND6yOlY6PSEQvF2=	M3jGRnNCVkeHUh?=
DV-90	NUK3VndiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmXXTWM2OD12LkK5N\|k4KM7:TR?=	NVrTUo1{W0GQR1XS
MOLT-16	M{nYbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTRwM{GwNVYh\|ryP	NVjmXIJkW0GQR1XS
HuCCT1	M4TjNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{[wcWlEPTB;ND6zN\|czOyEQvF2=	Mo\aV2FPT0WU
A3-KAW	NVfFUZBQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7MbFdWUUN3ME20MlM2PTV{IN88US=>	NX7oeoRSW0GQR1XS
HOS	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnjzTWM2OD12LkO4OVY4KM7:TR?=	MWTTRW5ITVJ?
KS-1	NYD2So9oT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLD[JFKSzVyPUSuOFI1PTlizszN	M2HRWHNCVkeHUh?=
SNU-423	MorBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWroZnlUUUN3ME20MlQzPjh3IN88US=>	M3XiZXNCVkeHUh?=
BC-3	M1XoXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3ZTWM2OD12LkSzOFc4KM7:TR?=	NWixb2hsW0GQR1XS
SCC-9	MlHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnHtTWM2OD12LkS0Nlk6KM7:TR?=	M1jtNnNCVkeHUh?=
C8166	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWjJR\|UxRTRwNEe3OVMh\|ryP	MUXTRW5ITVJ?
NCI-H358	NETsfIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX7EWIhjUUN3ME20MlQ5PTN{IN88US=>	MorVV2FPT0WU
GT3TKB	M{H1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTRwNEi4NlIh\|ryP	NIfOR45USU6JRWK=
NCI-SNU-1	M1fCTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mne4TWM2OD12LkS5O\|AyKM7:TR?=	M{nZfnNCVkeHUh?=
Ca9-22	NEHXUmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M36wTmlEPTB;ND61OVUyPiEQvF2=	M1HOdXNCVkeHUh?=
L-363	M1S0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmfITWM2OD12LkW1PVk3KM7:TR?=	MljVV2FPT0WU
Calu-1	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTRwNUi3NFch\|ryP	M3LIZ3NCVkeHUh?=
OE19	M2[zUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3Tw[GlEPTB;ND62N\|E1PSEQvF2=	Ml3yV2FPT0WU
COR-L23	NXq2XGNpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLGTWM2OD12Lk[3Nlgh\|ryP	M{DjfHNCVkeHUh?=
A431	NFjoelRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUe2Oo9SUUN3ME20MlY5OjJ6IN88US=>	M3n0cXNCVkeHUh?=
MKN1	MmHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{K5V2lEPTB;ND63NFY3PSEQvF2=	NGqxfoFUSU6JRWK=
SH-4	M1rVNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2PBd2lEPTB;ND63NlY{OyEQvF2=	NV;Jd5h[W0GQR1XS
SNB75	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnfuTWM2OD12Lke0OlYh\|ryP	M{HhSnNCVkeHUh?=
SW780	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHyTWM2OD12Lke2PFQ6KM7:TR?=	NGLHNmpUSU6JRWK=
GOTO	M4HIWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPqU4hyUUN3ME20Mlc6Ojl\|IN88US=>	NIG5O4xUSU6JRWK=
U-266	M4XpTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn30TWM2OD12Lkm0PVE6KM7:TR?=	M3nSb3NCVkeHUh?=
KURAMOCHI	NV7teIxlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmLYTWM2OD13LkCyPFM1KM7:TR?=	MoLNV2FPT0WU
NMC-G1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGHCXmFKSzVyPUWuNFkyOzlizszN	M3XqfXNCVkeHUh?=
COLO-684	M1nVeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYKxe5ZsUUN3ME21MlI2OzdzIN88US=>	MkT4V2FPT0WU
NTERA-S-cl-D1	NWfqPFVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFm5SJpKSzVyPUWuNlkzOThizszN	NWTuOo1XW0GQR1XS
RD	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTVwMkm3O\|Eh\|ryP	M1X4VHNCVkeHUh?=
A2058	MkHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;XS3dKSzVyPUWuN\|A1OzhizszN	NWPaOZE6W0GQR1XS
NCI-H2009	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTVwM{C1N\|gh\|ryP	NXf3eGJGW0GQR1XS
8-MG-BA	M{TvRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MofHTWM2OD13LkO3NFc4KM7:TR?=	MkHQV2FPT0WU
LC4-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1z5emlEPTB;NT6zPVMxOyEQvF2=	MkPHV2FPT0WU
A101D	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\UWmtKSzVyPUWuN\|k3QDlizszN	NF\VVGdUSU6JRWK=
ES8	M{TLOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX:zV2tFUUN3ME21MlQyPDB7IN88US=>	MX3TRW5ITVJ?
SF126	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTVwNEG0OlUh\|ryP	M4\sOXNCVkeHUh?=
GDM-1	M{j4[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnrKTWM2OD13LkSxO\|gyKM7:TR?=	MlG4V2FPT0WU
TE-6	NHPC[lBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NITuS2FKSzVyPUWuOFQ2PjlizszN	MVHTRW5ITVJ?
SR	M1rjZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTVwNUO2OFUh\|ryP	M2CwS3NCVkeHUh?=
HOP-62	NGfNXolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDKcIcxUUN3ME21MlU3QDh5IN88US=>	NVjoUYQyW0GQR1XS
HCC2157	M3jDe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfOTWM2OD13LkW2PFk3KM7:TR?=	Mm[2V2FPT0WU
TE-15	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\zdGlEPTB;NT61O\|c4QSEQvF2=	Mo\UV2FPT0WU
BFTC-905	MknFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX3JR\|UxRTVwNkC0NlEh\|ryP	NUTZdHp1W0GQR1XS
TE-9	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFjMNnJKSzVyPUWuOlE4QDhizszN	NH74OHpUSU6JRWK=
647-V	MlrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkjOTWM2OD13Lk[yNFQzKM7:TR?=	NULvTJk3W0GQR1XS
KG-1	NYXBS\|lXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXuUHUxUUN3ME21Mlc1ODB3IN88US=>	NVLZXllCW0GQR1XS
KYSE-510	MmfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\lSYNKSzVyPUWuO\|k2QDFizszN	MkjkV2FPT0WU
SK-MES-1	M3PoNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTVwOEW4PVEh\|ryP	NXvKTmtXW0GQR1XS
OVCAR-3	Ml;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHz5ToFKSzVyPUWuPFgzODZizszN	NFXETVNUSU6JRWK=
LB1047-RCC	MknpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXq1PJl1UUN3ME21MlkxOTR6IN88US=>	MoHsV2FPT0WU
HEL	MlzRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGmzRW5KSzVyPU[uNFIyQDhizszN	MYPTRW5ITVJ?
KARPAS-45	NE\TcI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\1TWM2OD14LkCzO\|g4KM7:TR?=	M4HGSXNCVkeHUh?=
NCI-H1304	M1nSdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml3hTWM2OD14LkGyOFk4KM7:TR?=	NVrObGVJW0GQR1XS
PC-3	NVjwWnNYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHPQU3RKSzVyPU[uNVMxPzJizszN	MXTTRW5ITVJ?
Calu-3	NFTkS3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFjDOGxKSzVyPU[uNVQ3QDlizszN	NWG4ZZZSW0GQR1XS
NCI-H1648	M1XYc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTZwMUWxOkDPxE1?	MV\TRW5ITVJ?
HSC-3	MlyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn32TWM2OD14LkG3N\|k3KM7:TR?=	NFPkOGJUSU6JRWK=
COLO-824	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmLnTWM2OD14LkK3PFY5KM7:TR?=	NX3GOpVCW0GQR1XS
COLO-680N	NWC0e4dQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LrW2lEPTB;Nj6zO\|Y{QCEQvF2=	NVjrdIs3W0GQR1XS
SK-NEP-1	M1qyfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M17HW2lEPTB;Nj60NFM3KM7:TR?=	M1PtPXNCVkeHUh?=
SCC-25	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4G3VWlEPTB;Nj60NlQ6OyEQvF2=	M1i2fXNCVkeHUh?=
SF295	NVvyb5RDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXn2bmNYUUN3ME22MlQ1QThizszN	MX\TRW5ITVJ?
no-10	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jieWlEPTB;Nj60O\|g1KM7:TR?=	MojqV2FPT0WU
NCI-H838	M2TJcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTZwNUG3NFMh\|ryP	NGG4OHpUSU6JRWK=
M059J	Ml62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NITB[4RKSzVyPU[uOVU3OjVizszN	NYryV4FMW0GQR1XS
Calu-6	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\5V2lEPTB;Nj62OVQ{PSEQvF2=	NEHSe2FUSU6JRWK=
TE-12	M1rnSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3Hwd2lEPTB;Nj63NlM4PyEQvF2=	MXrTRW5ITVJ?
639-V	MlTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\OcFMzUUN3ME22Mlc2OTJ5IN88US=>	M3PvPXNCVkeHUh?=
ESS-1	M{DFcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF3mZolKSzVyPU[uO\|YxPzJizszN	NUniV4VtW0GQR1XS
C-4-II	MmXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIj1TFBKSzVyPU[uPFMyOTdizszN	NWLVSXVsW0GQR1XS
23132-87	NEOwcnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTZwOUC5NFEh\|ryP	NIP0NYVUSU6JRWK=
MEG-01	NVHmWlZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PVZmlEPTB;Nj65N\|U1PiEQvF2=	NVvmOmU4W0GQR1XS
GI-1	M2DNUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWPJR\|UxRTZwOUSzOFgh\|ryP	MkDGV2FPT0WU
NCI-H2347	MnnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF;BcGJKSzVyPU[uPVQ4OTVizszN	Ml;EV2FPT0WU
MS-1	M4LJdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnvrTWM2OD14Lkm1NVkzKM7:TR?=	NIDEfJhUSU6JRWK=
SK-MEL-30	NXmzZotxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXvXSId4UUN3ME22Mlk3OzF3IN88US=>	MV3TRW5ITVJ?
YKG-1	MkT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXFVJJEUUN3ME23MlAzPjd6IN88US=>	MofhV2FPT0WU
HT-3	MmfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTdwMEO0PUDPxE1?	NU\ofog5W0GQR1XS
NCI-H2126	NX;ZZW1kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFzxRXVKSzVyPUeuNFk4QTFizszN	Ml24V2FPT0WU
GI-ME-N	MojLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLae2NiUUN3ME23MlE3QTB4IN88US=>	MVLTRW5ITVJ?
LB771-HNC	NVT5dJR4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTdwMUiwN\|gh\|ryP	MUXTRW5ITVJ?
LCLC-97TM1	NHLm[3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo[3TWM2OD15LkKxNlc{KM7:TR?=	MVrTRW5ITVJ?
HO-1-N-1	MmjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4HaT2lEPTB;Nz6yOFAzPCEQvF2=	MmHsV2FPT0WU
HCC1143	Mo\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEC5b25KSzVyPUeuN\|c5QThizszN	M2DZV3NCVkeHUh?=
HuO9	NFHOUoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4LxTGlEPTB;Nz60PFc6PCEQvF2=	MmHpV2FPT0WU
IST-SL2	M1O4NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIf5dmhKSzVyPUeuOVIzPzJizszN	NEDFbotUSU6JRWK=
MLMA	MmjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkC5TWM2OD15LkW0Olg6KM7:TR?=	MUPTRW5ITVJ?
22RV1	NWfFcHdwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{focmlEPTB;Nz62O\|k4PSEQvF2=	MXXTRW5ITVJ?
ONS-76	Mn;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTdwNkm0NVYh\|ryP	M{X5SnNCVkeHUh?=
ECC12	NVG4TllmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHKTWM2OD15LkeyPVAyKM7:TR?=	M2X1dXNCVkeHUh?=
HT-1080	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MniwTWM2OD15Lke4OVU2KM7:TR?=	MVjTRW5ITVJ?
SF268	NXPPTJlbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjZSWJKSzVyPUeuPFM2PiEQvF2=	NGjsSZhUSU6JRWK=
COLO-800	NWrqVI9jT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTdwOUC2PFUh\|ryP	NIP4fY5USU6JRWK=
BB30-HNC	MljlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfE[YxKSzVyPUeuPVQ2PTNizszN	NGHhVFVUSU6JRWK=
CAKI-1	MnfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\Pb2lEPTB;OD6wOlUzOSEQvF2=	M2\XfnNCVkeHUh?=
GCIY	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlfvTWM2OD16LkKzO\|E{KM7:TR?=	NITIenFUSU6JRWK=
MKN28	M3nr[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGXOZYtKSzVyPUiuNlQ2QThizszN	MnG1V2FPT0WU
IPC-298	NVewO3hQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1Tl[GlEPTB;OD6yO\|cxQSEQvF2=	M3TyWnNCVkeHUh?=
NCI-H1650	M2PS[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIT6fXVKSzVyPUiuNlkyQDVizszN	MVjTRW5ITVJ?
KP-N-YS	M4PZcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHKTWM2OD16LkK5N\|A5KM7:TR?=	MoH6V2FPT0WU
J82	NYDyOIFMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXtTWM2OD16LkO0NVI1KM7:TR?=	NVHmUFJ1W0GQR1XS
SK-HEP-1	NYOwV3RVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlPoTWM2OD16LkO1O\|I{KM7:TR?=	NWqyPFljW0GQR1XS
PANC-03-27	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nrN2lEPTB;OD6zOlkzKM7:TR?=	NVLNOJZOW0GQR1XS
KP-4	NYr0dGY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTaTWM2OD16LkSxPFU{KM7:TR?=	Ml3vV2FPT0WU
RERF-LC-MS	MlTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLqSodRUUN3ME24MlQ5PTl3IN88US=>	M2m2R3NCVkeHUh?=
C-33-A	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTzWYJIUUN3ME24MlYyPTJ7IN88US=>	NIDVOJVUSU6JRWK=
PA-1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXLJR\|UxRThwNk[2PVQh\|ryP	MnS1V2FPT0WU
TE-5	NWHiW4hoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYL3cIhxUUN3ME24MlcxOjl4IN88US=>	MmC2V2FPT0WU
MHH-PREB-1	M{K3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\IRZZzUUN3ME24Mlc{OTB5IN88US=>	Mo\PV2FPT0WU
C3A	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkHFTWM2OD16Lke2OVYyKM7:TR?=	MlnLV2FPT0WU
SK-OV-3	Mo[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFrxd29KSzVyPUiuO\|k4PzJizszN	Mk\pV2FPT0WU
AM-38	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRThwOEC0N\|kh\|ryP	NXTBV2JIW0GQR1XS
LoVo	M2XRU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXzDWIU6UUN3ME24Mlk2PTZ4IN88US=>	Mmi1V2FPT0WU
MKN45	MlO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGTXe41KSzVyPUiuPVYxPjNizszN	MU\TRW5ITVJ?
NH-12	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFfJNJhKSzVyPUmuNFI2PDJizszN	NHHGSWJUSU6JRWK=
CAMA-1	M3;rcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH:1T4NKSzVyPUmuNFYxOTJizszN	MlfBV2FPT0WU
HT-29	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXSxXoRFUUN3ME25MlEzOzd\|IN88US=>	M124eHNCVkeHUh?=
DMS-273	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXyWmJKSzVyPUmuNVI2KM7:TR?=	NHrTWGFUSU6JRWK=
NCI-H719	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1m2PGlEPTB;OT6xPFM6OSEQvF2=	MlLkV2FPT0WU
SF539	M{XHb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPkTWM2OD17LkKxNFk5KM7:TR?=	NUnlWoVUW0GQR1XS
Daoy	Mnj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofsTWM2OD17LkK0NVQ{KM7:TR?=	M13VbnNCVkeHUh?=
HCC70	MmXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1i5ZmlEPTB;OT6yO\|MxQSEQvF2=	M{i2NXNCVkeHUh?=
MFH-ino	NV7YNm1HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvnTWM2OD17LkK5NFA4KM7:TR?=	M{XyOHNCVkeHUh?=
UACC-62	M{jtWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEiwV3lKSzVyPUmuN\|czQTdizszN	MknRV2FPT0WU
C2BBe1	NG\VVlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGLldVdKSzVyPUmuN\|k3PTJizszN	M1Hmc3NCVkeHUh?=
KNS-42	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVrJR\|UxRTlwNEO0NFch\|ryP	NETnPWJUSU6JRWK=
SK-LMS-1	M1H2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTlwN{W1N\|Uh\|ryP	MojuV2FPT0WU
SK-CO-1	NXOweVBWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHmxbnhKSzVyPUmuO\|YzOzVizszN	MV7TRW5ITVJ?
SN12C	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTlwN{[4NFYh\|ryP	MmT3V2FPT0WU
HTC-C3	NH;tRVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rLVGlEPTB;OT63O\|k5PCEQvF2=	M3q3fnNCVkeHUh?=
OVCAR-4	NHi4NWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn7JTWM2OD17Lki0PFI5KM7:TR?=	MlTJV2FPT0WU
CHP-126	NWrvOGpUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\MSWlEPTB;OT65N\|I6KM7:TR?=	NXrS[4l5W0GQR1XS
NCI-H716	MkXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{D0fGlEPTB;OT65N\|MzOiEQvF2=	MoLoV2FPT0WU
U-698-M	M2\SV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1r4dWlEPTB;OT65PVch\|ryP	NGDz[\|FUSU6JRWK=
EFO-21	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWrUeWJkUUN3ME2xNE4xODl\|IN88US=>	MmfsV2FPT0WU
RXF393	MmiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzyTWM2OD1zMD6xN\|kzKM7:TR?=	MWLTRW5ITVJ?
ChaGo-K-1	NYLDRnNwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4f4eWlEPTB;MUCuNVc4PiEQvF2=	MmLwV2FPT0WU
SJRH30	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmPhTWM2OD1zMD6xPFQ1KM7:TR?=	NEjn[5FUSU6JRWK=
LU-65	M1W2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4\Te2lEPTB;MUCuNlk1OyEQvF2=	NIfzNlNUSU6JRWK=
OS-RC-2	NXvwbHBET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUjJR\|UxRTFyLkOyNlch\|ryP	NIrxOGJUSU6JRWK=
YT	Mnf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4rxSmlEPTB;MUCuOFAxOSEQvF2=	MVrTRW5ITVJ?
COLO-679	M1zvWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknFTWM2OD1zMD60Nlg2KM7:TR?=	NUXsN3MzW0GQR1XS
CAS-1	M1TveWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mmn6TWM2OD1zMD60OlA5KM7:TR?=	NGTobGlUSU6JRWK=
NCI-H2052	M4q1SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX;FSnlOUUN3ME2xNE42OTB3IN88US=>	M1vJbnNCVkeHUh?=
NCI-H2452	NWrwPHB3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTFyLk[xPFEh\|ryP	MnviV2FPT0WU
SW13	M1KzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjaTWM2OD1zMD62N\|c1KM7:TR?=	M1HtNXNCVkeHUh?=
HuP-T4	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTFyLkewOlgh\|ryP	NF33NHlUSU6JRWK=
UMC-11	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFmxcXRKSzVyPUGwMlk{PzNizszN	M4XzXXNCVkeHUh?=
EGI-1	MoDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2DGN2lEPTB;MUCuPVQ2PSEQvF2=	M{LVT3NCVkeHUh?=
JiyoyeP-2003	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\uTWM2OD1zMT6wPFkzKM7:TR?=	NYruNW9RW0GQR1XS
J-RT3-T3-5	M37WfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HsNWlEPTB;MUGuNVIxQSEQvF2=	NELNZmVUSU6JRWK=
DoTc2-4510	NEXEdFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fvc2lEPTB;MUGuNVM5QSEQvF2=	NYnxdGRwW0GQR1XS
HLE	M{DIXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLDTWM2OD1zMT6yNVE6KM7:TR?=	MkH5V2FPT0WU
SW626	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTFzLkK4PFkh\|ryP	MXjTRW5ITVJ?
COR-L105	M1TTUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGHMWWRKSzVyPUGxMlMzOzdizszN	M{DadnNCVkeHUh?=
ES6	NEHYeGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2nWOGlEPTB;MUGuOVc3KM7:TR?=	M{\SVnNCVkeHUh?=
SNU-449	MnTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HBUmlEPTB;MUGuOlA4OiEQvF2=	MkD4V2FPT0WU
GR-ST	M1;LUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIT1bldKSzVyPUGxMlYyQDFizszN	M1nme3NCVkeHUh?=
BL-41	MlfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoXpTWM2OD1zMT63NVc{KM7:TR?=	M{G1dXNCVkeHUh?=
GB-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvvTWM2OD1zMT63OlE6KM7:TR?=	MX;TRW5ITVJ?
COLO-320-HSR	M4fSbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYjTSoJ{UUN3ME2xNU45PTF7IN88US=>	M2\aZXNCVkeHUh?=
L-540	NHrVcZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn32TWM2OD1zMT64PVkh\|ryP	NYK0dog6W0GQR1XS
NCI-H69	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mon2TWM2OD1zMj6wNVM6KM7:TR?=	M1r2[3NCVkeHUh?=
769-P	M{LGRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIKzUXJKSzVyPUGyMlAyQSEQvF2=	MnX0V2FPT0WU
A172	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTF{LkGyNFch\|ryP	MVjTRW5ITVJ?
CAL-27	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3LCdmlEPTB;MUKuNVM3QSEQvF2=	MlHqV2FPT0WU
NCI-H1437	MlrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk\xTWM2OD1zMj6xOFQ4KM7:TR?=	MnHTV2FPT0WU
REH	M4fqe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIX2[5FKSzVyPUGyMlE2PzNizszN	NYftOWxiW0GQR1XS
KINGS-1	Ml;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIP1bItKSzVyPUGyMlM1OjFizszN	MUHTRW5ITVJ?
NCI-H1792	Mlf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUPxTXZGUUN3ME2xNk4{QDVzIN88US=>	Mlf3V2FPT0WU
SK-MM-2	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVfWSYN3UUN3ME2xNk41ODh5IN88US=>	MVPTRW5ITVJ?
8505C	M1zNbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTF{Lk[xNkDPxE1?	M{eyXnNCVkeHUh?=
HAL-01	MorIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUGwSY9HUUN3ME2xNk43OTd2IN88US=>	NYnRb5dVW0GQR1XS
NCI-H2141	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HO[2lEPTB;MUKuOlU5KM7:TR?=	MVLTRW5ITVJ?
HCC1806	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mmr6TWM2OD1zMj62PVUzKM7:TR?=	M4jERnNCVkeHUh?=
LU-134-A	M2L6Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTF{LkmzJO69VQ>?	Ml3XV2FPT0WU
HT	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRTF{Lkm0N\|ch\|ryP	M2DlXXNCVkeHUh?=
OE33	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jVdmlEPTB;MUKuPVQ2PiEQvF2=	M173c3NCVkeHUh?=
ES4	NWPzeWh{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVizbYQ1UUN3ME2xNk46PDh5IN88US=>	MX\TRW5ITVJ?
SW948	NF7BZ5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2H5dmlEPTB;MUOuNFE{KM7:TR?=	M4TVOHNCVkeHUh?=
LB2241-RCC	M33BTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTF\|LkG0Olkh\|ryP	NYTITnR[W0GQR1XS
CCF-STTG1	M1j5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWnJR\|UxRTF\|LkSwN\|kh\|ryP	NX:yVllSW0GQR1XS
RPMI-8402	NHXM[WxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXRN2N3UUN3ME2xN{42ODNzIN88US=>	M3T0VXNCVkeHUh?=
DEL	NUjJcJlST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGrZNldKSzVyPUGzMlU2ODNizszN	M3L0T3NCVkeHUh?=
NB5	NYK3VG9vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjnTWM2OD1zMz61OVA{KM7:TR?=	Mm[1V2FPT0WU
NUGC-3	NWrQUYp3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LnOGlEPTB;MUOuO\|Q2OyEQvF2=	M2nGXXNCVkeHUh?=
CAL-72	MknqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPuc4VKSzVyPUG0MlE6ODZizszN	M{nSTnNCVkeHUh?=
VMRC-RCZ	NF60OVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnjSTWM2OD1zND6yN\|Yh\|ryP	Ml;jV2FPT0WU
YAPC	NYP3cHI{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DiZ2lEPTB;MUSuNlQxPyEQvF2=	MVXTRW5ITVJ?
ES5	Mn;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDCTWM2OD1zND6yOVk6KM7:TR?=	NHnLUYZUSU6JRWK=
CAL-12T	NI\ybIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4j6[2lEPTB;MUSuOFM{PiEQvF2=	M{i2SnNCVkeHUh?=
GAMG	NUTNSGpET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XBZ2lEPTB;MUSuOVU4PyEQvF2=	M1LC[nNCVkeHUh?=
BT-20	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWmyNohiUUN3ME2xOE46Ozh2IN88US=>	NH7MeWdUSU6JRWK=
KALS-1	NH7GZ4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnywTWM2OD1zNT6wNVU5KM7:TR?=	NV3sRYZJW0GQR1XS
LS-123	Ml3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofCTWM2OD1zNT6wNVY2KM7:TR?=	MWfTRW5ITVJ?
LK-2	MofZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3rJcGlEPTB;MUWuNFg3OiEQvF2=	NUG5ZVk6W0GQR1XS
NCI-H1770	NELBeldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mnn2TWM2OD1zNT6yPFY5KM7:TR?=	NH;jUoxUSU6JRWK=
MIA-PaCa-2	NEXHZYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIrmV4pKSzVyPUG1MlQyPjNizszN	NVH5N5hIW0GQR1XS
DB	M2jNfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkTJTWM2OD1zNT62PVQyKM7:TR?=	NFrtcmFUSU6JRWK=
Becker	NX31cphRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLxTWM2OD1zNT64PVI3KM7:TR?=	NHHLU21USU6JRWK=
HT-144	Mlr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEj4eWFKSzVyPUG1Mlk1QTdizszN	NEjRRZBUSU6JRWK=
NCI-H2405	NV\wXYxIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmO3TWM2OD1zNj6yNlE5KM7:TR?=	MUXTRW5ITVJ?
TK10	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnwcGxHUUN3ME2xOk4{PzR{IN88US=>	MmP3V2FPT0WU
THP-1	Mnz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTF4LkS2OlUh\|ryP	MojxV2FPT0WU
LB373-MEL-D	NHi3VVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\ZVmlEPTB;MU[uOlE{QCEQvF2=	MmryV2FPT0WU
SJSA-1	NGDTSZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTF4LkmyNVkh\|ryP	NH;ObHJUSU6JRWK=
EB2	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3fFUmlEPTB;MUeuO\|QzPiEQvF2=	M{DuWnNCVkeHUh?=
MN-60	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NInMV45KSzVyPUG3Mlc6OzZizszN	MnuxV2FPT0WU
A253	NXTJO\|J5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIrIOZhKSzVyPUG3MlgzPSEQvF2=	NEfKd4JUSU6JRWK=
CESS	MmDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULL[HhQUUN3ME2xO{46OzJ4IN88US=>	MmTSV2FPT0WU
EW-11	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofnTWM2OD1zNz65PVU5KM7:TR?=	MlvIV2FPT0WU
TE-8	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTF6LkC2Olkh\|ryP	Mnn4V2FPT0WU
UACC-257	M13iZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUTJR\|UxRTF6LkKwOlIh\|ryP	MVrTRW5ITVJ?
NCI-H226	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3OUW1KSzVyPUG4MlgzQTlizszN	NW\3dYJ4W0GQR1XS
NCI-H748	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\3TWM2OD1zOD64OVg2KM7:TR?=	MnraV2FPT0WU
NCI-H1299	MlzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{i0[GlEPTB;MUiuPFkyQCEQvF2=	NHjuWWRUSU6JRWK=
IST-MEL1	MofIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX7JR\|UxRTF7LkG3OVQh\|ryP	MWTTRW5ITVJ?
HCC1187	NXzqcYhRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTF7LkG3PVYh\|ryP	NFLjcFBUSU6JRWK=
HT-1376	M{HHPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HKSmlEPTB;MUmuNlAzQSEQvF2=	NWHZXZNTW0GQR1XS
SK-MEL-2	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnhOXl2UUN3ME2xPU4zOTV3IN88US=>	NI\ud2tUSU6JRWK=
U031	MnvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzqemJ2UUN3ME2xPU4zOjF7IN88US=>	NYrPeZdpW0GQR1XS
NCI-H524	NFn1UFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVftUm9lUUN3ME2xPU42PzJ3IN88US=>	MoW3V2FPT0WU
KU812	NYq5S3IyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nvZWlEPTB;MUmuOVk1PCEQvF2=	NITIS\|VUSU6JRWK=
NB10	M4LGbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmW4TWM2OD1zOT62NlY5KM7:TR?=	M3fKc3NCVkeHUh?=
NOS-1	MnzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mne1TWM2OD1{MD6xOVc4KM7:TR?=	M17Qd3NCVkeHUh?=
EW-7	NF:0N5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmPwTWM2OD1{MD6xOlI5KM7:TR?=	MlvSV2FPT0WU
Raji	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfjbmtKSzVyPUKwMlI2PjhizszN	NGLoe\|VUSU6JRWK=
LB2518-MEL	M1nGOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTJyLkO5OVMh\|ryP	NVjoNW1rW0GQR1XS
PANC-10-05	M2LJSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV\JR\|UxRTJyLkS2NVMh\|ryP	NXPUNoZ6W0GQR1XS
MZ2-MEL	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTJyLkW4NVQh\|ryP	M33DUnNCVkeHUh?=
MFE-280	Mmi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{HJOmlEPTB;MkGuN\|E5QCEQvF2=	NIr4S41USU6JRWK=
RKO	MlXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlS3TWM2OD1{MT6zNlAzKM7:TR?=	NYX4ZZlUW0GQR1XS
KMOE-2	Mo\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\Sc2pKSzVyPUKxMlMzQDhizszN	NGjXN\|lUSU6JRWK=
K5	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGXxd\|hKSzVyPUKxMlM5QTNizszN	M12zNHNCVkeHUh?=
NCI-H64	NFnFSpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MljrTWM2OD1{MT60O\|U3KM7:TR?=	M3vOZXNCVkeHUh?=
K-562	NFfaTY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHP6OZdKSzVyPUKxMlQ6PzFizszN	M{LY[HNCVkeHUh?=
HCE-T	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHW4fJpKSzVyPUKxMlUxQTRizszN	NXrHVGZnW0GQR1XS
COLO-792	M2L2d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTJzLkW4Nlch\|ryP	M1frc3NCVkeHUh?=
PFSK-1	MkjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3ju[GlEPTB;MkGuOlg{PyEQvF2=	NXu2Omc4W0GQR1XS
DOK	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV7JR\|UxRTJzLke2PFch\|ryP	MVvTRW5ITVJ?
NCI-H1882	MnToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYewS4p4UUN3ME2yNU45PTl4IN88US=>	Mlj6V2FPT0WU
KNS-81-FD	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTJzLki2N\|Eh\|ryP	M37rNXNCVkeHUh?=
OCUB-M	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFW4eI5KSzVyPUKxMlk3QDhizszN	MmPKV2FPT0WU
NCI-H1694	NVHGOIpiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTJzLkm4OlMh\|ryP	NIXOTGhUSU6JRWK=
LS-513	NV7ab2E6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnPkTWM2OD1{Mj6wN\|Y4KM7:TR?=	MnLGV2FPT0WU
NCI-H2122	NImzfFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{e2e2lEPTB;MkKuNVY4PyEQvF2=	NWniXm0yW0GQR1XS
IMR-5	NXXVWW5tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTJ{LkK4O{DPxE1?	MVfTRW5ITVJ?
SNU-C2B	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVXVTIdLUUN3ME2yNk43PzR4IN88US=>	MYjTRW5ITVJ?
A498	NEm3dGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M37YRmlEPTB;MkKuPFE4PyEQvF2=	MlH1V2FPT0WU
NCI-H727	MmPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHn4dnpKSzVyPUKyMlg5OzZizszN	NHnCcIdUSU6JRWK=
SW1573	NV\qXHhiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M17a[GlEPTB;MkOuNFY1PiEQvF2=	MYXTRW5ITVJ?
RO82-W-1	MkX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHPvVGNKSzVyPUKzMlI2OTFizszN	MoTwV2FPT0WU
SKG-IIIa	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFXjbYVKSzVyPUKzMlM2PDZizszN	MWHTRW5ITVJ?
MC-CAR	NY\ROGdqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3TTbmlEPTB;MkOuOVE5OyEQvF2=	MnTIV2FPT0WU
NCI-H446	NEjHb\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFjBS5RKSzVyPUKzMlYxQTNizszN	MVLTRW5ITVJ?
PC-14	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXnxfo5yUUN3ME2yN{43PjJ\|IN88US=>	MYDTRW5ITVJ?
TGBC1TKB	M3jxcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjwTWM2OD1{Mz63OFYyKM7:TR?=	M4DJTHNCVkeHUh?=
EFM-19	M{Tmdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{n5UWlEPTB;MkSuNVg1PCEQvF2=	M3u4[nNCVkeHUh?=
SK-N-DZ	NEXMW5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUjl[5VYUUN3ME2yOE41QTd5IN88US=>	NXrNeZRuW0GQR1XS
NCI-H661	M1rROmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnFVpFKSzVyPUK0MlUzOTdizszN	MXXTRW5ITVJ?
SW1990	MnzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoLITWM2OD1{ND61PFg{KM7:TR?=	MXzTRW5ITVJ?
SW684	MlXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnrGTWM2OD1{ND63OlI1KM7:TR?=	NUTUN3h3W0GQR1XS
Ca-Ski	NYGxe2lST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnz5TWM2OD1{ND65NlM4KM7:TR?=	M1O0N3NCVkeHUh?=
TGW	MlzCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn[5TWM2OD1{NT6yN\|M4KM7:TR?=	NITVOI5USU6JRWK=
CaR-1	M2i5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vrb2lEPTB;MkWuN\|U4KM7:TR?=	MXPTRW5ITVJ?
D-247MG	Mn3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MonwTWM2OD1{NT60O\|Q{KM7:TR?=	M3jpenNCVkeHUh?=
CCRF-CEM	MmTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLhRZJYUUN3ME2yOU44PDV7IN88US=>	NUXNO4VUW0GQR1XS
CAPAN-1	NUXXSHVOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV;vW4xNUUN3ME2yOU44PTBzIN88US=>	MmXUV2FPT0WU
CP50-MEL-B	NXHafIhPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTJ3Lkm5NFEh\|ryP	M3\pOnNCVkeHUh?=
FADU	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHHiZ4xKSzVyPUK2MlUyPTJizszN	NILBcolUSU6JRWK=
Daudi	NUTSUXBxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4XaZmlEPTB;Mk[uOVE2QCEQvF2=	MVXTRW5ITVJ?
U-87-MG	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2TmUGlEPTB;Mk[uOVMxPSEQvF2=	MUDTRW5ITVJ?
DSH1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTJ4LkW0NFYh\|ryP	M1y4WXNCVkeHUh?=
KYSE-520	NV3SW456T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn7HTWM2OD1{Nj61OVU{KM7:TR?=	NHKxW45USU6JRWK=
HuH-7	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHO0OGVKSzVyPUK2MlkxQDZizszN	M2DBTHNCVkeHUh?=
U-2-OS	M{HkU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;z[WlKSzVyPUK3MlAzPzFizszN	M2\GVnNCVkeHUh?=
LU-99A	Mk\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfxTWM2OD1{Nz6xO\|U1KM7:TR?=	NUT6d5VUW0GQR1XS
T98G	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPkTWM2OD1{Nz6xPVc{KM7:TR?=	M3f1dXNCVkeHUh?=
MZ7-mel	NWi2OpF6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTJ5LkW1OFgh\|ryP	NVfBOYdSW0GQR1XS
SNU-C1	NW\uN29RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWT4WVF3UUN3ME2yO{43PDlzIN88US=>	NHjZXGJUSU6JRWK=
MDA-MB-175-VII	NYj1RlY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYOxS3NPUUN3ME2yO{43QTd3IN88US=>	MUfTRW5ITVJ?
HuP-T3	NUjSboRXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTOTWM2OD1{OD6wOFk2KM7:TR?=	MnflV2FPT0WU
T-24	M2LofWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXvSRZBxUUN3ME2yPE4yQTJ3IN88US=>	NES3UVlUSU6JRWK=
HDLM-2	NYPTb3c3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlj5TWM2OD1{OD6yOFU6KM7:TR?=	MmPZV2FPT0WU
NCI-H1651	M4j5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\l[WhFUUN3ME2yPE4zPTl{IN88US=>	M1jzV3NCVkeHUh?=
SK-N-AS	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV3JR\|UxRTJ6LkOxO\|Eh\|ryP	MYjTRW5ITVJ?
NY	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPlN5NvUUN3ME2yPE43PTd7IN88US=>	NGP5Z3NUSU6JRWK=
D-283MED	NH3kepdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mln2TWM2OD1{OD64O\|A5KM7:TR?=	NITIU3ZUSU6JRWK=
KLE	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUju[oQxUUN3ME2yPE46QTB4IN88US=>	NXi2O3FiW0GQR1XS
NCI-H28	M{PxVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYTJR\|UxRTJ7LkCxNkDPxE1?	M1Lzc3NCVkeHUh?=
TE-1	MnLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWTJR\|UxRTJ7LkKxOlch\|ryP	M3jENXNCVkeHUh?=
SK-MEL-24	NWH3N\|VtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFr5cZFKSzVyPUK5MlU1PjZizszN	M2PGeHNCVkeHUh?=
CAL-54	NWXPcHZpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3zuNWlEPTB;MkmuOlA1PiEQvF2=	NIPESWtUSU6JRWK=
A673	M4DHOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fRNmlEPTB;MkmuO\|MzKM7:TR?=	MmrCV2FPT0WU
HEC-1	NUnidlVNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUf0dlRkUUN3ME2zNE4xODV\|IN88US=>	M3LRbHNCVkeHUh?=
LS-411N	M3TzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2[weWlEPTB;M{CuNVQ4PSEQvF2=	MULTRW5ITVJ?
SW962	NEDRdGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn3rTWM2OD1\|MD6yOFc4KM7:TR?=	MnvCV2FPT0WU
OVCAR-8	Mmi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M325XmlEPTB;M{CuOlc6PCEQvF2=	NX;kR5JSW0GQR1XS
NCI-H630	MlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmqyTWM2OD1\|MD64PVU{KM7:TR?=	NInPZ4JUSU6JRWK=
D-263MG	NGLZN3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTNzLkC0NlQh\|ryP	MV7TRW5ITVJ?
NCI-H596	M1\wW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mni2TWM2OD1\|MT6wOlIyKM7:TR?=	NV;2WI1[W0GQR1XS
BB49-HNC	MorzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV;wWHV{UUN3ME2zNU4yOTJizszN	NXi0OoxHW0GQR1XS
KYSE-70	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3qx[2lEPTB;M{GuN\|AxQCEQvF2=	MWnTRW5ITVJ?
LAN-6	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MojDTWM2OD1\|MT60PVkzKM7:TR?=	NVTweFBrW0GQR1XS
NCI-H2228	NVr6NnFrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX:3[5g6UUN3ME2zNU42PjJ3IN88US=>	M3roT3NCVkeHUh?=
SW620	Mo\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvxTWM2OD1\|MT62Nlg{KM7:TR?=	MXHTRW5ITVJ?
KM-H2	M1vpUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrRTXNKUUN3ME2zNU44OzB4IN88US=>	MXjTRW5ITVJ?
DJM-1	M2jJS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{DkZ2lEPTB;M{KuNVM5PiEQvF2=	M{\kW3NCVkeHUh?=
SW48	NXXxcWFLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LWUmlEPTB;M{KuN\|gzPSEQvF2=	Mm[4V2FPT0WU
NCI-H1793	NWLB[IY1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjUXmhKSzVyPUOyMlYyPjNizszN	MkXrV2FPT0WU
LU-165	NULnNVdOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWjIe5ZQUUN3ME2zN{4xODhizszN	NVPwcolnW0GQR1XS
EHEB	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\LWWlEPTB;M{OuNFQ6PCEQvF2=	MX\TRW5ITVJ?
NCI-H441	M2C5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXMO4lKSzVyPUOzMlIzOzVizszN	MXrTRW5ITVJ?
LOXIMVI	M2fMWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvDTFZwUUN3ME2zN{4{Pjd7IN88US=>	M3KxWHNCVkeHUh?=
MC-IXC	NUO1RZdST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFS3OZVKSzVyPUOzMlU3PTVizszN	M2fVbHNCVkeHUh?=
NCI-H522	Mm\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTN\|Lk[1OEDPxE1?	MmryV2FPT0WU
IA-LM	Mn7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3n0RWlEPTB;M{OuOlc1PiEQvF2=	MWnTRW5ITVJ?
NCI-H1417	NXuyZ4ZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2L3eWlEPTB;M{OuPVU5PSEQvF2=	MVvTRW5ITVJ?
HCC2218	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFe5eHFKSzVyPUO1MlIyQDVizszN	MX7TRW5ITVJ?
HC-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUTwU5BXUUN3ME2zOU41ODJ2IN88US=>	NGOzW3FUSU6JRWK=
HH	NHfNfIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXmbHg6UUN3ME2zOU41OTRzIN88US=>	NWT4VZR6W0GQR1XS
EFE-184	NFnNeohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vhcmlEPTB;M{WuOlgzQSEQvF2=	M4XGXHNCVkeHUh?=
NCI-H1355	NXWzPIFZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4G2fGlEPTB;M{WuO\|cyQCEQvF2=	NUfkfm95W0GQR1XS
BV-173	M2PUbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPHVVd4UUN3ME2zOU45OjZ2IN88US=>	MWXTRW5ITVJ?
NEC8	M3:x[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn64TWM2OD1\|Nj60PVI1KM7:TR?=	MmPTV2FPT0WU
SW1463	NWjuOYd7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH7PdIlKSzVyPUO2MlY2PjZizszN	M3fiNXNCVkeHUh?=
KYSE-140	MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVTJR\|UxRTN4LkeyPVgh\|ryP	Mo\PV2FPT0WU
no-11	MlvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVfycpN[UUN3ME2zOk45PTN4IN88US=>	MYjTRW5ITVJ?
HCC1937	M1fMWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\UUYNSUUN3ME2zO{4xOTV2IN88US=>	M{G5SHNCVkeHUh?=
LNCaP-Clone-FGC	NXXzPJgyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnzWTWM2OD1\|Nz6xPVA{KM7:TR?=	MnfoV2FPT0WU
KARPAS-422	NVv5fol1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mmj0TWM2OD1\|Nz60OFMyKM7:TR?=	NHzSVJlUSU6JRWK=
RCM-1	NHPUbIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHvTWM2OD1\|Nz61N\|U5KM7:TR?=	NVHWSppEW0GQR1XS
A375	NX\icFdwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIXVfmpKSzVyPUO3Mlc3PDdizszN	NYP0UGRVW0GQR1XS
TGBC24TKB	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTN6LkCyN\|kh\|ryP	M{fGeXNCVkeHUh?=
MDA-MB-453	NWjBR3R1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH23Rm1KSzVyPUO5MlAzOThizszN	NWmyelRPW0GQR1XS
Capan-2	M{DWe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrHUolKSzVyPUO5MlA2ODlizszN	MX3TRW5ITVJ?
SW756	NIHKT3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjOW5ZPUUN3ME2zPU42ODlzIN88US=>	MXXTRW5ITVJ?
KU-19-19	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\aZWlEPTB;M{muOlI5OiEQvF2=	NEXnSXlUSU6JRWK=
NCI-H2170	MoPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHVNokyUUN3ME2zPU46QTd5IN88US=>	M{\uTnNCVkeHUh?=
COLO-678	M1;sZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTRyLkW5OUDPxE1?	MkDmV2FPT0WU
PF-382	M{DaWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHO4[4VKSzVyPUSwMlc1QDdizszN	MXfTRW5ITVJ?
OAW-42	M3rNemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1XCc2lEPTB;NEKuNlk1OiEQvF2=	MUXTRW5ITVJ?
LB996-RCC	MnrZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPUfVJKSzVyPUSyMlgxODhizszN	M3XN[3NCVkeHUh?=
SAS	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nrcmlEPTB;NEOuOFI5QCEQvF2=	NF\rPZFUSU6JRWK=
MRK-nu-1	MmK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3IO5dEUUN3ME20OE44PDF2IN88US=>	M1jVZnNCVkeHUh?=
EoL-1-cell	NXTXTmhpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmHZTWM2OD12ND65NVM3KM7:TR?=	NX7McVZkW0GQR1XS
NCI-H2342	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4faRmlEPTB;NEWuNVEyPyEQvF2=	MUfTRW5ITVJ?
NCI-H1703	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmLjTWM2OD12Nj6wOVkzKM7:TR?=	Mmf2V2FPT0WU
NCI-H187	NW[3SFFbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUjDRpY2UUN3ME20Ok4yQDZ7IN88US=>	MWXTRW5ITVJ?
CP66-MEL	NHTub4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTR4LkK3PFkh\|ryP	MWXTRW5ITVJ?
HCC1569	NIHYPFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\xTWM2OD12Nj61PVE4KM7:TR?=	MYPTRW5ITVJ?
BL-70	MoS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFzrfXRKSzVyPUS2Mlc4OzdizszN	NXvpV\|VXW0GQR1XS
Saos-2	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTR5LkOxNlMh\|ryP	M37CNHNCVkeHUh?=
LC-1F	MmTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTR5Lk[xNFUh\|ryP	Mn3sV2FPT0WU
KY821	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LhUWlEPTB;NEeuOlQ{PCEQvF2=	MmPqV2FPT0WU
PSN1	NEfYUpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmLITWM2OD12OD6xOFAyKM7:TR?=	NFXNbW9USU6JRWK=
RT4	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXPJR\|UxRTR6LkizO\|ch\|ryP	NHq5N2FUSU6JRWK=
LS-1034	M3:4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUnCd5R6UUN3ME20PE45QTV2IN88US=>	NUnaelNQW0GQR1XS
NCI-H1395	NXu2ZYhTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIn0flhKSzVyPUS5MlA1QTJizszN	M2S1fHNCVkeHUh?=
EKVX	NVLvdYNPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2HrVGlEPTB;NEmuOlc{OSEQvF2=	M3fkcXNCVkeHUh?=
IST-MES1	M3rUeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1PZRmlEPTB;NEmuPFk1PCEQvF2=	MmfoV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-FAK / FAK / p-Talin / Talin ; PubMed: 26530902 Cancer Res Dose response of PF-562271 on the phosphorylation of FAK-Y397 or Talin-S425 in PC3-mm2 cells. p-Src / Src / p-paxillin / Paxillin / ICAM-1 ; PubMed: 29417941 Acta Pharmacol Sin MDA-MB-231 cells transfected with FAK-specific siRNAs or treated for 12 h with PF-562271 at the indicated concentrations were subjected to immunoblotting with indicated antibodies.	26530902 29417941
Immunofluorescence	p-FAK; PubMed: 26530902 Cancer Res Immunostaining of PC3-mm2 cells showed that phosphorylated FAK is localized at focal adhesions (inset).	26530902
Growth inhibition assay	Cell viability; PubMed: 28953264 Nutrients MTT assay showed inhibition of cell proliferation and viability in HCT116 (B) and SW480 (D) cell lines treated with resveratrol and/or different concentrations of FAK-Inhibitor (PF-562271: 0.01, 0.1, 1, and 10 µM) cultured in monolayer for 12 h. Data shown are representative of three independent sets of experiments. Values were compared with the control and statistically significant values with p < 0.05 are designated by an asterisk () and p < 0.01 are designated by two asterisks (*).	28953264

In vivo

PF-562271 (< 33 mg/kg p.o.) inhibits FAK phosphorylation in tumors in a dose- and time-dependent manner in U87MG-bearing mice. PF-562271 (50 mg/kg p.o. bid) results in 86% tumor growth inhibition in BxPc3 xenografts mice and 45% tumor growth inhibition in PC3-M xenografts mice. PF-562271 (25 mg/kg, bid) results in 2-fold greater apoptosis in treated tumors in mice bearing H125 lung xenografts. ^[1] PF-562271 (33 mg/kg, p.o.) inhibits extensive movement of the tumor cells over 24 hours in mice. PF-562271 (33 mg/kg, p.o.) results in altered E-cadherin dynamics in mice, which correlates with reduced E-cadherin–dependent collective cell movement. ^[3] PF-562271 (25 mg/kg, p.o. bid) results in 62% tumor growth inhibition in PC3M-luc-C6 subcutaneuous local implant xenograft mouse model. ^[4] PF-562,271 (5 mg/kg, oral) results in significant and similar increases in osteocalcin and cancellous bone parameters and a decrease in tumor growth and signs of bone healing in rats implanted with MDA-MB-231 cells in the tibia. ^[5]

Protocol

Animal Research:^[1]	- Collapse Animal Models: Athymic female mice bearing BxPc3 or PC3-M xenografts. Dosages: 50 mg/kg Administration: Oral gavage (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	100 mg/mL warmed (197.04 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+40% PEG 300+5% Tween 80+50% ddH2O For best results, use promptly after mixing.	5 mg/ml

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PF-562271 SDF

Molecular Weight	507.49
Formula	C₂₁H₂₀F₃N₇O₃S
CAS No.	717907-75-0
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CN(C1=C(C=CC=N1)CNC2=NC(=NC=C2C(F)(F)F)NC3=CC4=C(C=C3)NC(=O)C4)S(=O)(=O)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

FAK Signaling Pathway Map

Related FAK Products

PND-1186 (VS-4718) ^New

PND-1186 (VS-4718, SR-2156) is a reversible and selective FAK inhibitor with IC50 of 1.5 nM. PND-1186 selectively promotes tumor cell apoptosis. Phase 1.
PF-431396 ^New

PF-431396 is a dual PYK2/FAK inhibitor with IC50 of 11 nM and 2 nM, respectively.
Defactinib (VS-6063) ^New

Defactinib (VS-6063, PF-04554878) is a selective, and orally active FAK inhibitor. Phase 2.
PF-00562271 Besylate

PF-00562271 Besylate (PF-562271) is the benzenesulfonate salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. Phase 1.
TAE226 (NVP-TAE226)

TAE226 (NVP-TAE226) is a potent FAK inhibitor with IC50 of 5.5 nM and modestly potent to Pyk2, ~10- to 100-fold less potent against InsR, IGF-1R, ALK, and c-Met. TAE226 (NVP-TAE226) induces apoptosis.
PF-573228

PF-573228 is an ATP-competitive inhibitor of FAK with IC50 of 4 nM in a cell-free assay, ~50- to 250-fold selective for FAK than Pyk2, CDK1/7 and GSK-3β. PF-573228 induces apoptosis.
PF-562271 HCl

PF-562271 HCl is the hydrochloride salt of PF-562271, which is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs. Phase 1.
Ibrutinib (PCI-32765)

Ibrutinib (PCI-32765) is a potent and highly selective Brutons tyrosine kinase (Btk) inhibitor with IC50 of 0.5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc. Ibrutinib is applicable as a Btk ligand in the synthesis of a series of PROTACs including P13I.
Dasatinib

Dasatinib (BMS-354825) is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively. Dasatinib induces autophagy and apoptosis with anti-tumor activity.
Saracatinib (AZD0530)

Saracatinib (AZD0530) is a potent Src inhibitor with IC50 of 2.7 nM in cell-free assays, and potent to c-Yes, Fyn, Lyn, Blk, Fgr and Lck; less active for Abl and EGFR (L858R and L861Q). Saracatinib induces autophagy. Phase 2/3.

Features:The 1st Src inhibitor to show inhibition of the Src pathway in human tumor tissue.

Choose Your Country or Region

By Signaling Pathways

By product type

PF-562271